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Immediate percutaneous coronary intervention is associated with
better survival after out-of-hospital cardiac arrest: experience of
Clermont-Ferrand hospital
Amina Asadi (1), Nicolas Barber-Chamoux (2), Pascal Motreff (2), Jean
René Lusson (2)
(1) CHU Ibn Rochd, Cardiologie, Casablanca, Maroc – (2) CHU Gabriel
Montpied, Cardiologie, Clermont Ferrand, France
Background: The out-of-hospital cardiac arrest represent the leading cause
of death worldwide. Several therapeutic elements such as early reperfusion
developed in recent years to reduce the high morbidity and mortality observed
in this situation. The objective of this study was to evaluate the influence of
emergency coronary angiography (CAG) and primary percutaneous coronary
intervention (PCI) on the outcome of patients survivors after out-of-hospital
cardiac arrest.
Methods: Between January 2012 and June 2013, a total of 54 consecutive
patients survivors of out-of-hospital cardiac arrest underwent systematic emer-
gency coronary angiography.
Results: Thirty five of the 54 patients had clinically significant coronary
disease on angiography, 23 of whom had coronary-artery occlusion (43 %).
Angioplasty was attempted in 20 patients and was technically successful in 18.
The in-hospital survival rate was 48 %. Multivariate logistic-regression anal-
ysis revealed that angioplasty was an independent predictor of survival
(95 percent confidence interval, 3.1 to 750.1; P =0.006).
Conclusions: Acute coronary-artery occlusion is frequent in survivors of
out-of-hospital cardiac arrest. Accurate diagnosis by immediate coronary
angiography can be followed in suitable candidates by coronary angioplasty,
which seems to improve survival.
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Determination of the influence of genetic variants in predetermined
genomic region on the occurrence of CVD in humans, in association
with circulating lipids level as a risk factor
Ghina Bouabout
Institut Clinique de la Souris, Cardiovasculaire, Strasbourg, France
Cardiovascular diseases (CVDs) are a major cause of mortality (up to 40%
death). CVDs are highly inheritable, suggesting a major role of genetic fac-
tors. Identifying key genes remain difficult as individual CVD risks are often
linked to multiple undetermined genes and their interaction with environ-
mental parameters. Significant progress have been made recently with the
identification of nearly 120 genomic regions including variants associated
with CVD accrued risk. These studies involve genome-wide associated data
and are most helpful but cannot allow to accurately identify gene and the spe-
cific impact of each genetic variant in different physiological and metabolic
events associated with CVDs. Starting from the Ludwigshafen Risk and Car-
diovascular Health study, with a large cohort of patients (~3800) with a data-
base of clinical and metabolic parameters, we have selected candidate gene
and their variants associated with CVDs. To determine the functional impact
of these variants, we produce mutant mice, reproducing targeted genomic
changes found for each gene. These mice are fed atherogenic diet at 11-
12 weeks of age and studied to determine metabolic and physiological conse-
quences of these variants. Workflow focuses on arterial blood pressure by
NIBP, progression of atherosclerotic plaques size and composition and ste-
atosis formation by echography of the main arteries branching (carotid, aorta,
renal arteries…). We measure also body composition and glucose tolerance by
qNMR and OGTT respectively. Blood is collected to assess plasmatic cho-
lesterol levels (HDL, LDL, TG) and organs are weighted (heart, kidney,
spleen…) and used for RNA seq analysis. The identification of genetic factors
responsible for phenotypic traits associated with CVDs and characterization of
their impact on physiological and molecular level will allow us not only to
better understand the genetic mechanisms promoting CVDs, but also to iden-
tify markers for better prevention and treatment of CVDs.
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Incidence and predictors of bleeding events in ST-Elevation Myo-
cardial infarction (STEMI) revascularized within the first 12 hours.
Marie-Alexandre Chaix (1), Sandra Jost (2), José Labarere (1), Loic Belle (3),
Gérald Vanzetto (1)
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Background: Antithrombotic therapies reduce the risk of recurrent
ischemic events in acute STEMI, but are responsible for an increase in
bleeding events.
Aim: To describe the incidence and identify the predictive factors of
bleeding events in patients revascularized within the first 12 hours of STEMI
at Grenoble University Hospital.
Methods: We analyzed data from 276 consecutive pts prospectively
included in the RESURCOR registry and determined the incidence, severity
(TIMI, and BARC bleeding scores), sites, and associated complications of
bleeding events. Crusade score, clinical history and therapies administered
before coronary angiography (CA) were collected.
Results: All 276 pts underwent CA, 74 (27%) after thrombolysis and 202
(73%) for primary-PCI (radial route = 82%). One or more bleeding event
occurred in 27 pts (9.8%): TIMI major n=13 (4.7%) and minor n=14 (5.1%).
Patients with bleeding complications were more often female (p=0.012), were
older (p=0.016), had lower body weight (p=0.023), presented more often with
cardiogenic shock (p=0.001), required more often circulatory support
(p<0.00001), and had higher CRUSADE score (32.4+15.7 vs. 25.2+13.7
p=0.016) than pts without bleeding. Mortality was 30.8, and 4.0% in pts with
major, and no bleeding respectively (p<0.0001). Independent predictors of
bleeding events were an older age, female gender, low body weight and
presence of heart failure on admission. In emergency situation, bleeding risk
evaluation by the clinician modified the management of STEMI, with less
GPIIbIIa inhibitors (p=0.004) and thrombolytic agents (p=0.04) prescribed in
pts with a high risk of bleeding.
Conclusion: The incidence of bleedings in STEMI remains stable despite
more powerful antithrombotic agents, probably in relation with radial access
and awareness of the bleeding risk by the clinician. Our study also confirms
that bleeding events are strongly associated with in-hospital mortality.
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Essential role of platelet PI3Kβ and GSK3 in thrombus stability at
high shear rate
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During platelet activation, class I phosphoinositide 3-kinase β (PI3Kβ)
generate the lipid second messengers PtdIns(3,4,5)P3 which is an important
players in the organization of the platelet signaling machinery downstream of
activator receptors and integrins. Since PI3Kβ inhibition prevents occlusive
thrombus formation with a limited increase in bleeding risk and acceptable
safety in humans, this kinase has been proposed as a potential antithrombotic
drug target. However, the role of platelet PI3Kβ in integrated in vivo or ex
vivo models of thrombosis upon high shear rate condition found in stenosed
arteries remains incompletely documented.
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